Guardant Health公司宣布,Evernorth旗下的Evicore已决定将其Shield血液检测纳入结直肠癌(CRC)筛查的承保范围。这项覆盖计划将于2027年1月1日正式生效。
Guardant Health公司宣布,Evernorth旗下的Evicore已决定将其Shield血液检测纳入结直肠癌(CRC)筛查的承保范围。这项覆盖计划将于2027年1月1日正式生效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.